Prospective Study on How Initial PSMA PET Scans Predict Outcomes in Men Newly Diagnosed with Untreated Prostate Cancer

What this Trial Is About

Researchers are studying the prognostic value of prostate-specific membrane antigen PSMA positron emission tomography PET scans in men newly diagnosed with prostate cancer who have not yet received treatment. The goal is to understand how initial PSMA PET imaging can predict progression-free survival and to develop a prognostic tool called the PSMA-VISION score. This study addresses a gap by focusing exclusively on untreated patients at initial staging to improve risk assessment accuracy. This observational study collects data from patients who have undergone PSMA PET as their first staging method before any treatment. The study will analyze baseline PSMA PET parameters, such as SUVmax, lesion count, and metastatic stage, along with clinical variables to create and validate a prognostic model. It also compares this new model with existing tools like NCCN risk categories and the PPP nomogram, aiming to enhance prediction of progression-free and overall survival. Participants will be followed for at least two years to assess progression-free survival and up to ten years for overall survival. Researchers will gather clinical data, imaging results, and pathology reports at regular intervals to evaluate disease progression and survival outcomes. Data will be securely stored and analyzed using statistical models to develop accurate risk stratification tools for prostate cancer management.

A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve Prostate Cancer